GlassScriptPhysician profile
Alexander B Bernal
NPI 1912972266
$7,062.07
in general payments reported to CMS, 2019-2025
32 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $567 · 2021: $589 · 2022: $1,160 · 2023: $1,319 · 2024: $1,426 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,201 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,201.15 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,653.16 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Qol Medical, LLC | $922.45 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $664.02 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $560.82 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $503.69 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Aimmune Therapeutics, INC. | $459.09 | 2024 | |
| Gilead Sciences, INC. | $376.50 | 2019-2025 | |
| Genzyme Corporation | $299.83 | 2022-2025 | |
| Madrigal Pharmaceuticals | $227.58 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $191.78 | 2022-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $170.31 | 2022-2025 | Dupixent |
| Celgene Corporation | $169.99 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $142.69 | 2023-2025 | Iqirvo, Bylvay |
| Amgen INC. | $123.91 | 2019-2025 | Uplizna |
| Intercept Pharmaceuticals, INC. | $101.01 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.20 | 2022-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.95 | 2023-2024 | Cyltezo |
| Organon LLC | $69.00 | 2022-2025 | Hadlima |
| Lilly USA, LLC | $54.15 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $36.84 | 2025 | Voquezna |
| Covidien LP | $23.42 | 2019 | |
| Welch Allyn | $16.90 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.93 | 2025 | Givlaari |
| Celltrion USA INC. | $15.51 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $14.99 | 2023 | Injectafer |
| Ferring Pharmaceuticals INC. | $14.48 | 2021 | |
| Ucb, INC. | $14.39 | 2019 | |
| Novo Nordisk INC | $13.26 | 2019 | |
| Ardelyx, INC. | $12.71 | 2023 | Ibsrela |
| Baxter Healthcare | $12.67 | 2022 | |
| Pfizer INC. | $12.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Bernal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.